Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of elbasvir/grazoprevir for 8 weeks in treatment-naïve HCV genotype 1b patients with non-severe fibrosis
2016-001363-37Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elbasvir + grazoprevir in chronic hepatitis C (CHC), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: SVR12. Started Jun 2017; status: completed.
02
Drugs
elbasvir + grazoprevir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2016-001363-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001363-37.